Despite Increased Use And Sales of Statins In India, Per Capita Prescription Rates Remain Far Below High-Income Countries

Authors: Niteesh K. Choudhry, Sagar Dugani, William H. Shrank, Jennifer M. Polinski, Christina E. Stark, Rajeev Gupta, Dorairaj Prabhakaran, Gregory Brill, Prabhat Jha


Statin use has increased substantially in North America and Europe, with resultant reductions in cardiovascular mortality. However, little is known about statin use in lower-income countries. India is of interest because of its burden of cardiovascular disease, the unique nature of its prescription drug market, and the growing globalization of drug sales.

We conducted an observational study using IMS Health data for the period February 2006–January 2010. During the period, monthly statin prescriptions increased from 45.8 to 84.1 per 1,000 patients with coronary heart disease—an increase of 0.80 prescriptions per month. The proportion of the Indian population receiving a defined daily statin dose increased from 3.35 percent to 7.78 percent. Nevertheless, only a fraction of those eligible for a statin appeared to receive the therapy, even though there were 259 distinct statin products available to Indian consumers in January 2010. Low rates of statin use in India may reflect problems with access to health care, affordability, underdiagnosis, and cultural beliefs.

Because of the growing burden of cardiovascular disease in lower-income countries such as India, there is an urgent need to increase statin use and ensure access to safe products whose use is based on evidence. Policies are needed to expand insurance, increase medications’ affordability, educate physicians and patients, and improve regulatory oversight.  More


Choudhry NK, et al. 2014. Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries. Health Affairs. 33(2): 273-282.